Intellia raises ~$293.5M in public offering of 6.55M shares at $45.80

Intellia Therapeutics, Inc.

Offering of 6,550,219 shares of common stock at $45.80 per share; underwriter option for up to 982,532 additional shares.
Net proceeds estimated at $293.5M after underwriting discount and expenses; expected close December 2, 2022.
Underwriting agreement with Goldman Sachs & Co. LLC; customary representations and indemnification provisions.
Offering conducted under existing shelf registration statement (File No. 333-251022); prospectus supplement dated November 30, 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Intellia Therapeutics, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC valued at approximately $293.5 million (effective 2022-11-30).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC
Value: approximately $293.5 million
Effective: 2022-11-30

Exact text from the filing

On November 30, 2022, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC (the “Underwriter”), related to a public offering (the “Offering”) of 6,550,219 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $45.80 per share.

View on SEC.gov

Browse all material agreements →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-296686

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.